Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um ensaio para investigar benralizumabe em crianças com doenças eosinofílicas (CLIPS)

27 de outubro de 2026 atualizado por: AstraZeneca

Fase 3, ensaio aberto para avaliar segurança, farmacocinética e eficácia do benralizumabe em crianças com doenças eosinofílicas (CLIPS)

The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.

Visão geral do estudo

Descrição detalhada

This study is open-label, multicentre, basket study to evaluate the safety, PK, pharmacodynamic (PD), efficacy, and immunogenicity of repeat dosing of benralizumab subcutaneous (SC) every 4 weeks (Q4W) in male and female children with rare eosinophilic diseases.

Paediatric participants with eosinophilic granulomatosis with polyangiitis (EGPA) will be enrolled in the first cohort.

Paediatric participants with hypereosinophilic syndrome (HES) will be enrolled in the second cohort. Additional cohorts in other eosinophilic diseases may be added in future protocol amendments.

The study consists of 3 periods:

  1. Screening period: 1 to 4 weeks
  2. Open-label treatment period: 52 weeks
  3. Open-label extension period: at least 52 weeks (plus safety follow-up [SFU] weeks after last investigational product [IP] administration)

All eligible participants will receive benralizumab SC Q4W during the 52-week open-label treatment period.

All participants who complete the 52-week open-label treatment period on IP will be offered the opportunity to continue into an extension period. The extension period is intended to allow each participant at least an additional one year of treatment with benralizumab.

Tipo de estudo

Intervencional

Inscrição (Estimado)

14

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • São Paulo, Brasil, 01232-010
        • Recrutamento
        • Research Site
    • Ontario
      • Toronto, Ontario, Canadá, M5G1X8
        • Recrutamento
        • Research Site
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80045
        • Recrutamento
        • Research Site
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45229
        • Recrutamento
        • Research Site
      • Highland Hills, Ohio, Estados Unidos, 44106-2624
        • Recrutamento
        • Research Site
      • Lille, França, 59037
        • Recrutamento
        • Research Site
      • Montpellier, França, 34295
        • Suspenso
        • Research Site
      • Rotterdam, Holanda, 3015 GD
        • Recrutamento
        • Research Site
      • Petah Tikva, Israel, 49202
        • Recrutamento
        • Research Site
      • Guadalajara, México, 44620
        • Recrutamento
        • Research Site
      • Kielce, Polônia, 25-734
        • Recrutamento
        • Research Site
      • Warsaw, Polônia, 04-730
        • Ainda não está recrutando
        • Research Site
      • Altındağ, Turquia (Türkiye), 06230
        • Recrutamento
        • Research Site
      • Istanbul, Turquia (Türkiye), 34093
        • Recrutamento
        • Research Site
      • Ahmedabad, Índia, 380052
        • Recrutamento
        • Research Site

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

6 anos a 17 anos (Filho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

All Cohorts:

  • Male or female participants must be aged 6 to < 18 years of age at the time of signing the assent form and their caregiver signing the informed consent form.
  • Body weight greater than (>=) 15 kilograms (kg).

EGPA Cohort:

  • Therapy with corticosteroids: The prescribed dose of oral corticosteroids (OCS) (greater than [>] 0.1 milligrams per kilogram per day (mg/kg/day), max dose of 50 milligrams per day (mg/day) must be stable (that is, no adjustment of the dose) for at least 4 weeks prior to baseline (Visit 2).
  • Immunosuppressive therapy: If receiving immunosuppressive therapy, the dosage must be stable for at least 4 weeks prior to baseline (Visit 2).

HES Cohort:

  • Documented HES diagnosis, defined as history of persistent eosinophilia >1500 cells/µL without secondary cause on 2 examinations ≥1 month apart and evidence of eosinophil-mediated organ involvement.
  • Symptomatic active HES, or history of a prior flare, or considered eligible based on disease severity per investigator judgement.
  • AEC ≥1000 cells/µL at screening (Visit 1).
  • Documented negative testing for Fip1-like 1 gene fused with the platelet-derived growth factor receptor alpha gene (FIP1L1-PDGFR) fusion tyrosine kinase gene translocation.

Exclusion Criteria:

All Cohorts:

  • Any current malignancy or history of malignancy.
  • History of anaphylaxis to any biologic therapy or vaccine.
  • Known, pre-existing, clinically significant endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, haematological, respiratory, or any other system abnormalities.
  • Previous receipt of benralizumab in an interventional clinical study.

EGPA Cohort:

  • Diagnosed with granulomatosis with polyangiitis (previously known as Wegener'granulomatosis) or microscopic polyangiitis.
  • EGPA relapse: any deterioration in EGPA and/or organ-threatening EGPA that per Investigator judgement renders participants unstable in their EGPA within 3 months prior to screening (Visit 1) and through first administration of IP at baseline (Visit 2).
  • Life-threatening EGPA: imminently life-threatening EGPA disease within 3 months prior to screening (Visit 1) and through first administration of IP at baseline (Visit 2), as per Investigator judgement.

HES Cohort:

  • Life-threatening HES or HES complications, as judged by the investigator.
  • Hypereosinophilia of unknown significance (HE-US).
  • Diagnosis of systemic mastocytosis.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: EGPA/HES Cohort: Benralizumab

Participants with greater than or equal to (>=) 35 kg weight will receive benralizumab dose-1 and participants with less than (<) 35 kg weight will receive benralizumab dose-2 as SC injection Q4W during the 52-week treatment period. All participants who complete the 52-week treatment period will be offered the opportunity to continue into an extension period.

Benralizumab will be administered as SC injection on Q4W.

Outros nomes:
  • FASENRA

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Number of Participants with Adverse Events (AEs)
Prazo: From screening (Week -4 to -1) until Week 52

The safety and tolerability of benralizumab will be evaluated.

From screening (Week -4 to -1) until Week 52
Serum Concentrations of Benralizumab
Prazo: Weeks 0, 12, 24, 25, 36, and 52

The PK of benralizumab will be evaluated.

Weeks 0, 12, 24, 25, 36, and 52

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
EGPA Cohort: Percentage of Participants with Remission at Week 24
Prazo: At Week 24

Remission defined as Paediatric Vasculitis Activity Score (PVAS) = 0 and oral corticosteroid (OCS) intake less than or equal to (<=) 0.1 mg/kg/day.

At Week 24
Number of Participants with Positive Antidrug Antibody (ADA)
Prazo: Weeks 0, 12, 24, 36, 48, and 52

The immunogenicity of benralizumab will be evaluated.

Weeks 0, 12, 24, 36, 48, and 52
Change From Baseline in Peripheral Blood Eosinophil Count
Prazo: From Baseline to Weeks 0, 12, 24, 36, 52

The PD effect of benralizumab on peripheral blood eosinophil count will be evaluated.

From Baseline to Weeks 0, 12, 24, 36, 52
EGPA Cohort: Time to First EGPA Relapse
Prazo: Up to 52 weeks

The efficacy of benralizumab on time to first relapse will be assessed. EGPA relapse will be defined as worsening or persistence of active disease since the last visit characterized by: a) Active vasculitis (PVAS > 0); OR b) Worsening of asthma symptoms (based on Asthma Control Questionnaire - Interviewer Administered [ACQ-IA]); OR c) Active nasal and/or sinus disease with worsening in at least one sino-nasal symptom question warranting any of the following: 1) Increase OCS; OR 2) Increase/addition of immunosuppressive medication; OR 3) Hospitalisation related to EGPA worsening.

Up to 52 weeks
HES Cohort: Time to first HES worsening/flare
Prazo: Up to 52 weeks

The effect of benralizumab on HES worsening/flares will be evaluated.

Up to 52 weeks
HES Cohort: Percentage of participants who experience a HES worsening/flare
Prazo: Up to 52 weeks

The effect of benralizumab on HES worsening/flares will be evaluated.

Up to 52 weeks
HES Cohort: Number of HES worsening/flares (annualised rate/year)
Prazo: Up to 52 weeks

The effect of benralizumab on HES worsening/flares will be evaluated. The annualised HES worsening/flare rate will be calculated as follows:

The total number of flares *365.25 / total duration of follow-up in the treatment period (days).

Up to 52 weeks
HES Cohort: Percentage of Participants requiring an increase in corticosteroid dose
Prazo: Up to 52 weeks

The effect of benralizumab on corticosteroid use will be evaluated.

Up to 52 weeks
HES Cohort: Time to first haematologic relapse
Prazo: Up to 52 weeks

The time to first haematologic relapse will be defined as the time from first dose of IP to the first post baseline visit with Absolute eosinophil count [AEC] ≥ 1000 cells/uL.

Up to 52 weeks
HES Cohort: Percentage of Participants with haematologic relapse
Prazo: Up to 52 weeks

The effect of benralizumab on haematologic measures of disease activity will be evaluated.

Up to 52 weeks
HES Cohort: Percentage of Participants who have AEC < 500 cells/μL for 24 weeks
Prazo: Up to 52 weeks

The effect of benralizumab on haematologic measures of disease activity will be evaluated.

Up to 52 weeks
HES Cohort: Patient Global Impression of Change (PGI-C) Score
Prazo: Weeks 12, 24, 36 and 48

The effect of benralizumab on participant/caregiver reported measures of disease severity and health status will be assessed. The PGI-C instrument captures the participant's overall evaluation of response to treatment, and rated on a 7-point PGI-C scale ranging from 1 ('much better') to 7 ('much worse').

Weeks 12, 24, 36 and 48

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

17 de abril de 2025

Conclusão Primária (Estimado)

20 de fevereiro de 2028

Conclusão do estudo (Estimado)

14 de maio de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

17 de julho de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

17 de julho de 2024

Primeira postagem (Real)

22 de julho de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

28 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

27 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • D3255C00004
  • 2023-508533-14-00 (Outro identificador: EU CT)
  • EMEA-001214-PIP09-21-M02(EGPA) (Outro identificador: Paediatric Investigational Plan Number)
  • EMEA-001214-PIP04-19-M02 (HES) (Outro identificador: Paediatric Investigational Plan Number)
  • 2023 (Concessão/Contrato do NIH dos EUA)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via there quest portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Prazo de Compartilhamento de IPD

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Critérios de acesso de compartilhamento IPD

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever